<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624701</url>
  </required_header>
  <id_info>
    <org_study_id>2009/925/B</org_study_id>
    <nct_id>NCT01624701</nct_id>
  </id_info>
  <brief_title>Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells</brief_title>
  <official_title>Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells: A Pilot Trial in Collaboration With the Massachusetts Institute of Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Whitehead Institute for Biomedical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood Services Group, Health Sciences Authority of Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot clinical trial to assess the feasibility and efficacy of expanding umbilical
      cord blood derived blood stem cells for transplantation using a combination of chemical
      factors and stromal co-culture. Bone marrow (BM) mesenchymal stromal cells (MSC) will be
      obtained from a separate bone marrow donor. One cord blood unit will be expanded by this
      method while another cord blood unit will be infused without manipulation. The expanded cord
      blood unit will help boost the initial recovery of blood counts after transplantation, though
      it is expected that the unexpanded cord blood unit will provide the cells which will lead to
      long term engraftment of blood stem cells. A third cord blood unit will be identified for
      standby should the cord blood unit expansion fail.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Clinical transplantation of two cord blood units: one ex vivo expanded while another
           unmanipulated unit to function as a back-up.

        2. Ten patients will be selected from those for whom:

             -  Allogeneic haematopoietic stem cell transplant is indicated (see details)

             -  No matched sibling or matched unrelated donor is available quickly enough for the
                transplant (no fully matched donor found within 1 month of initiation of donor
                search or donor found but not available for donation within 3 months of donor
                search).

             -  At least three unrelated donor cord blood unit can be identified with less than 2
                antigens mismatches with the patient but with insufficient cell dose to meet the
                patient's requirements. If clinical efficacy of this protocol is demonstrated, we
                will proceed to a multicentre clinical trial with more patients.

        3. The investigators will obtain haplo-identical MSC from the bone marrow of
           sibling/parent/offspring of the patient. Although there will be some MSC co-infused with
           the cord blood cells, this has been shown to be safe in trials of MSC given for patients
           with graft versus host disease (GVHD) and human leukocyte antigen (HLA) matching of MSC
           and recipient has been shown to be not important. bone marrow mesenchymal stroma cells
           (BM-MSCs) derived from related donor bone marrow with a minimum of 2/6 HLA match have
           been safe for use in patients.1 If the haplo-identical MSC donor is not available,
           matched unrelated donor MSC would also be used.

        4. Efficacy will be assessed by the following and compared to published literature as well
           as historical controls:

             -  Neutrophil and platelet engraftment

             -  Post transplant 100-day mortality

             -  Overall and progression-free survival If clinical efficacy of this protocol is
                demonstrated, the investigators will proceed to a multicentre clinical trial with
                more patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding expired
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 month</time_frame>
    <description>Number of subjects with infusional toxicities (including fever, renal dysfunction within 72 hours of infusion) and potential immunologic competition (absent chimerism of donor cells by 21 days post transplantation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>2 months</time_frame>
    <description>Neutrophil engraftment (ANC&gt;500/ul) in subjects as demonstrated by number of subjects with engraftment &lt;=21 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Lymphoma</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Expanded</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>'Ex vivo expanded cord blood cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ex vivo expanded cord blood cells</intervention_name>
    <description>Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.</description>
    <arm_group_label>Expanded</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be from the Department of Haematology, Singapore General Hospital, who
             have the diagnoses listed below and who meet the inclusion criteria. They have to be
             deemed suitable for trial by the respective attending doctor as well as a panel of at
             least three hematologists. Suitability will be reassessed by the Principal
             Investigator again

               1. Patients aged 12 years to 60 years.

               2. Patient has no currently available HLA-A, B, C, DRB1 and DQB1 matched related or
                  unrelated donor.

               3. Patient must have a hematologic malignancy requiring allogeneic haematopoietic
                  stem cell transplantation as further defined below (from National Marrow Donor
                  Program and American Society of Blood and Marrow Transplantation Guidelines) and
                  as further agreed upon by a panel of at least three hematologists specializing in
                  transplantation.

          -  Acute myelogenous leukemia (AML): High-risk AML including:

               -  Antecedent hematological disease (e.g., myelodysplasia (MDS))

               -  Treatment-related leukemia

               -  Induction failure

               -  1st complete remission (CR1) with poor-risk cytogenetics or molecular markers
                  (e.g. Flt 3 mutation, 11q23 etc)

               -  2nd complete remission (CR2) and beyond

          -  Acute lymphoblastic leukemia (ALL)

               -  CR1 up to age 35

               -  High-risk over age 35 including:

               -  Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23
                  rearrangements)

               -  High white cell count (&gt; 30,000/mm3) at diagnosis

               -  CNS or testicular leukemia

               -  No CR within 4 weeks of initial treatment

               -  Induction failure

               -  CR2 and beyond

          -  Myelodysplastic syndromes (MDS)

               -  Intermediate-1 (INT-1), intermediate-2 (INT-2) or high IPSS score which includes:

               -  &gt; 5% marrow blasts

               -  Other than good risk cytogenetics (not 5q- or normal)

               -  &gt; 1 lineage cytopenia

          -  Chronic myelogenous leukemia (CML)

               -  Disease progression

               -  Accelerated phase

               -  Blast crisis (myeloid or lymphoid)

          -  Follicular lymphoma

               -  Poor response to initial treatment

               -  After second or subsequent relapse

               -  Transformation to diffuse large B-cell lymphoma

          -  Aggressive T-cell or B-Cell lymphoma

               -  After second or subsequent relapse

               -  No CR with initial treatment

          -  Mantle Cell: After second or subsequent relapse

          -  Hodgkin's lymphoma

               -  No initial CR

               -  After second or subsequent relapse

          -  Multiple myeloma: Patients failing autologous transplantation with chromosome 13
             abnormalities, first response lasting less than 6 months, or Î²-2 microglobulin &gt; 3
             mg/L may be considered for this protocol after initial therapy.

        Exclusion Criteria:

          1. Inadequate Organ Function as defined by:

               -  Renal: Creatinine clearance &gt; 60ml/min

               -  Hepatic: Bilirubin, AST/ALT &lt; 2x upper limit of normal

               -  Pulmonary function: DLCOcorr &gt; 50% normal

               -  Cardiac: left ventricular ejection fraction &gt; 45%

          2. Karnofsky score (adults) &lt; 70% or Lansky score &lt; 50% (pediatrics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William YK Hwang, MBBS, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>November 26, 2015</last_update_submitted>
  <last_update_submitted_qc>November 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord blood</keyword>
  <keyword>unrelated donor</keyword>
  <keyword>allogeneic</keyword>
  <keyword>cell dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

